Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | POLQ | O75417 | 1/20 | 0.42 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2097680 | 0.87 | NPSR1 (0.47) | NPSR1ALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL4682247 | 0.85 | MTOR (0.48) | MTORMAOB | |
| SCHEMBL29116640 | 0.85 | TACR1 (0.51) | NPSR1CES2POLQP2RX1L3MBTL1 | |
| SCHEMBL31393782 | 0.84 | NPC1 (0.51) | NPSR1ALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL2094545 | 0.84 | MEN1 (0.49) | NPSR1ALDH1A1TSHRRAB9ACES2 | |
| SCHEMBL28643943 | 0.81 | NPC1 (0.53) | ALDH1A1TSHRNPC1RAB9AKIF11 | |
| SCHEMBL22946391 | 0.81 | NPC1 (0.47) | NPSR1ALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL10671760 | 0.81 | NPSR1 (0.55) | NPSR1ALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL19778 | 0.81 | NPSR1 (0.70) | NPSR1ALDH1A1TSHRNPC1RAB9A | |
| SCHEMBL4741127 | 0.81 | RAB9A (0.53) | NPSR1ALDH1A1NPC1RAB9ASRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2204368-B1 | 4-sulfonylpiperidine derivatives | MSD KK (JP) | 2014-05-21 | — | — | EP | disclosed |
| US-8163898-B2 | 4-sulfonylpiperidine derivatives | MSD K. K. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20100234392-A1 | 4-SULFONYLPIPERIDINE DERIVATIVES | MSD K.K. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2204368-A1 | 4-SULFONYLPIPERIDINE DERIVATIVES | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009090548-A2 | 3-AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS, S.A. (US) | 2009-07-23 | — | — | WO | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | NPSR1 202/4885ALDH1A1 412/4885TSHR 162/4885 |
| US-20100234392-A1 | 4-SULFONYLPIPERIDINE DERIVATIVES | CHRM2, CHRM1, CHRM3 | NPSR1 331/4885ALDH1A1 752/4885TSHR 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.